John Biguenet

DGAP-News: Abivax appoints Dr Sophie Biguenet, M.D., as Chief Medical Officer

Retrieved on: 
Monday, March 1, 2021
American writers, Abivax, John Biguenet, Writers

Abivax appoints Dr Sophie Biguenet, M.D., asChief Medical Officer

Key Points: 
  • Abivax appoints Dr Sophie Biguenet, M.D., asChief Medical Officer
    The issuer is solely responsible for the content of this announcement.
  • Abivax appoints Dr Sophie Biguenet, M.D., asChief Medical Officer
    PARIS, March 1, 2021 - 06:00 p.m. (CET) - Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company modulating the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today announces the appointment of Dr Sophie Biguenet as Chief Medical Officer, effective on March 1, 2021, based in Paris.
  • Dr Steens has been actively involved in the successful clinical transition of lead compound ABX464 into late-stage clinical testing in chronic inflammatory diseases.
  • Prior to joining Abivax, Dr Sophie Biguenet served as CMO at Versantis, a Swiss clinical-stage biotech company, where she successfully took the pipeline from pre-clinical to phase 2b.